Inotrem successfully reaches agreement with the FDA for a Phase 3 registration trial for nangibotide in septic shock
January 8, 2024
Paris (France), January 8. 2024. Inotrem, an advanced clinical stage biotech company specializing in immunotherapies for acute and chronic inflammatory syndromes, today announced the outcome